Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

SCD-HeFT update

This article was originally published in The Gray Sheet

Executive Summary

CMS will "undertake a complete review of the available literature" on prophylactic implantation of ICDs in patients with poor ventricular function, including SCD-HeFT, DINAMIT, DEFINITE and COMPANION clinical trials, CMS announces March 30. The agency also will assess evidence pertaining to selection of appropriate defibrillators for specific patient populations. The review responds to 1Medtronic's March 18 request that CMS amend its ICD coverage policy to include all patients with at least one year of remaining life expectancy, documented congestive heart failure for greater than 3 months and left-ventricular function of less than 35% - the indication evaluated in the SCD-HeFT trial. Following release of CMS' ICD coverage policy in 2003, the agency agreed to revisit its coverage criteria once SCD-HeFT results were unveiled (2"The Gray Sheet" March 15, 2003, p. 3)...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT020021

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel